Related references
Note: Only part of the references are listed.Zanubrutinib for treatment-naive and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study
Gavin Cull et al.
BRITISH JOURNAL OF HAEMATOLOGY (2022)
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma
Stephen Opat et al.
CLINICAL CANCER RESEARCH (2021)
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma
Constantine S. Tam et al.
BLOOD ADVANCES (2021)
Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase
Yuqin Song et al.
CLINICAL CANCER RESEARCH (2020)
ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM).
Constantine Si Lun Tam et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study
Constantine S. Tam et al.
BLOOD (2020)
Zanubrutinib for the treatment of patients with Waldenstrom macroglobulinemia: 3 years of follow-up
Judith Trotman et al.
BLOOD (2020)
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
Franck Morschhauser et al.
LANCET ONCOLOGY (2020)
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
John P. Leonard et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
Constantine S. Tam et al.
BLOOD (2019)
Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial
Constantine S. Tam et al.
BLOOD (2019)
Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib
Nathan M. Denlinger et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial
Nancy L. Bartlett et al.
BLOOD (2018)
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma
Ariela Noy et al.
BLOOD (2017)
Second-generation inhibitors of Bruton tyrosine kinase
Jingjing Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Follicular lymphoma international prognostic index
P Solal-Céligny et al.
BLOOD (2004)
Share Paper
